2.10

0.94% -0.02

After Hours: 2.10

Acrivon Therapeutics Inc (ACRV)

Overview News Price History Financials Discussions Forecast

Acrivon Therapeutics Inc stock is traded at $2.10, with a volume of 181.91K. It is down -0.94% in the last 24 hours and down -3.67% over the past month. Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Previous Close:

$2.12

Open:

$2.12

24h Volume:

181.91K

Relative Volume:

0.47

Market Cap:

$89.99M

Revenue:

Net Income/Loss:

$-77.27M

P/E Ratio:

-1.049

EPS:

-2.0019

Net Cash Flow:

$-66.29M

1W Performance:

+13.51%

1M Performance:

-3.67%

6M Performance:

+38.16%

1Y Performance:

+36.36%

1-Day Range:

$2.07

$2.13

1-Week Range:

$1.8706

$2.24

52-Week Range:

$1.27

$3.56

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name

Acrivon Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

617-207-8979

Address

480 ARSENAL WAY, SUITE 100, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-11-12

Latest SEC Filings

ACRV's Discussions on Twitter

Compare ACRV vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRV Acrivon Therapeutics Inc	2.10	89.99M	0	-77.27M	-66.29M	-2.0019
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-05-25	Resumed	Piper Sandler	Overweight
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform
Dec-15-23	Resumed	Jefferies	Buy
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform
May-08-23	Initiated	BMO Capital Markets	Outperform
Apr-27-23	Initiated	Ladenburg Thalmann	Buy
Apr-20-23	Initiated	H.C. Wainwright	Buy
Dec-12-22	Initiated	Cowen	Outperform
Dec-12-22	Initiated	Jefferies	Buy
Dec-12-22	Initiated	Piper Sandler	Overweight

View All

Acrivon Therapeutics Inc Stock (ACRV) Latest News

Sep 16, 2026

Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock - simplywall.st

Sep 16, 2026

Sep 15, 2026

What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock - Yahoo Finance

Sep 15, 2026

Sep 12, 2026